摘要
目的:观察阿托伐他汀钙联合盐酸多奈哌齐治疗轻、中度阿尔茨海默病(AD)的临床效果。方法:将我院74例轻、中度AD患者采用抽签法随机均分为对照组与联合治疗组。对照组给予盐酸多奈哌齐5mg,口服,qd;联合治疗组给予阿托伐他汀钙20mg+盐酸多奈哌齐5mg,口服,qd。两组总疗程均为1年。分别于治疗前及治疗后3、6、12个月进行血脂水平测定并采用简易精神状态检查表(MMSE)、临床痴呆程度量表(CDR)和日常生活能力量表(ADL)进行临床治疗效果评定。监测治疗前后的不良反应以及肌酐、尿素氮、天冬氨酸氨基转移酶、丙氨酸氨基转移酶含量的变化。结果:对照组治疗前后血脂(血清总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇)水平无显著变化(P>0.05),但联合治疗组较治疗前显著改善(P<0.01)。两组治疗后MMSE、CDR、ADL评分与治疗前比较均有显著性改善(P<0.05),且联合治疗组治疗6、12个月后MMSE、CDR、ADL评分较对照组显著改善(P<0.01)。两组均未见明显不良反应发生。结论:阿托伐他汀钙联合盐酸多奈哌齐降血脂的同时能改善轻、中度AD患者的认知功能,且安全性良好。
OBJECTIVE：To observe clinical efficacy of atorvastatin calcium combined with donepezil hydrochloride in the treatment of mild to moderate alzheimer disease（AD）.METHODS：74 patients with mild to moderate AD in our hospital were randomly divided into combination group and control group.The combination group received atorvastatin calcium 20 mg combined with donepezil 5 mg orally once a day,while the control group received donepezil hydrochloride 5 mg orally once a day for 1 year.The level of blood lipid and cognitive function were determined before treatment and 3,6,and 12 months after treatment.Mini-Mental State Examination（MMSE）,Clinical Dementia Rating（CDR）,and Activities of Daily Living（ADL） scores were used for the evaluation of cognitive function.The adverse drug reactions were recorded before and after treatment.The changes of creatinine,blood urea nitrogen,glutamic-oxalacetic transminase and glutamic-pyruvic transminase were also observed before and after treatment.RESULTS：After treatment,the levels of TC,LDL-C and HDL-C were significantly improved in combination group（P0.01）,whereas the control group did not show any such improvement（P0.05）.There were significant differences in scores of MMSE,CDR and ADL between 2 groups before and after treatment.The scores of MMSE,ADL and CDR were significantly improved in combination group 6 and 12 months after treatment,compared with control group（P0.01）.No significant adverse drug reaction was found in 2 groups.CONCLUSIONS：Atrovstatin calcium can relieve cognitive function of patients with mild to moderate AD with good safety.
出处
《中国药房》
CAS
CSCD
2013年第20期1855-1857,共3页
China Pharmacy
基金
重庆市医学科研计划项目(No.2012-2-222)
